NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,474.06 -1.86 (-0.01%) CRUDE OIL
78.37 +0.26 (+0.33%) GOLD FUTURES
2,320.20 +11.60 (+0.50%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
50,909.45 +500.10 (+0.99%)
Calliditas Therapeutics AB (publ) (LC8.F)
| Previous close | 9.44 |
| Open | 9.31 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 9.20 - 9.31 |
| 52-week range | 6.98 - 13.00 |
| Volume | |
| Avg. volume | 108 |
| Market cap | 495.125M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksXencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
PR NewswireCalliditas Therapeutics' 2023 Annual Report Published
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com
PR NewswireCalliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.
